

Chronic liver diseases and iron: a concise review with emphasis on hypotransferrinemia and hypohepcidinemia

Naciye Şemnur BÜYÜKAŞIK¹, Yahya BÜYÜKAŞIK^{2*}

¹Department of Gastroenterology, Atatürk Education and Research Hospital, Ankara, Turkey

²Department of Hematology, Faculty of Medicine, Hacettepe University, Ankara, Turkey

Received: 20.08.2015 • Accepted/Published Online: 01.01.2016 • Final Version: 17.11.2016

Abstract: Iron studies in chronic liver diseases (CLDs) have a long history. Currently we can mention certainties, uncertainties, and hopes related to this topic. It is certain that iron metabolism problems and hepatic siderosis are frequent in CLDs and they get more frequent as CLD progresses, but true iron overload is rare. There are conflicting literature data on the mechanism of siderosis, the role of iron in CLD pathogenesis, and the potential benefits of iron removal. We may hope that pharmacological approaches targeting iron metabolism disorders of CLD will be actively evaluated in the future. In this review, we aimed to present a general outlook of this extensively studied topic.

Key words: Iron, chronic liver disease, siderosis, hepcidin, transferrin

1. Introduction

There are extensive literature data on iron in chronic liver diseases (CLDs). In this review, we intended to summarize current information on hepatic siderosis and changes of iron metabolism seen in CLDs. We aimed to present a general perspective of this wide topic. Although this work is not a systematic review, we undertook a detailed literature review and integrated published research evidence to get answers for some relevant questions. Our literature review was conducted in March 2015 using the PubMed search engine. The following Boolean phrase was searched: “(cirrhosis or hepatitis) and iron”. References of the retrieved papers were also considered.

2. The link between liver and iron

The liver is an important organ in iron homeostasis. In addition to its involvement in iron storage, which means the presence of a large quantity of the iron storage protein ferritin within the liver, this organ also produces plasma iron carrier protein transferrin (TF) and the iron-regulatory hormone hepcidin (1,2). Another aspect of the relationship between iron and the liver is that this organ is the first one affected in iron overload disorders (3). Additionally, hepatic siderosis is frequently observed in CLDs.

3. Hepatic siderosis: is it always pathological?

The histological finding of hepatic stainable iron is frequently not associated with systemic overload or even liver iron

overload. In fact, minimal hepatic siderosis in otherwise healthy persons is possible, the significance of which is not known (4–6). Some of these cases may have at least some components of the metabolic syndrome, but higher grades of hepatic siderosis are commonly associated with systemic iron overload disorders and CLDs.

4. Hepatic siderosis in CLDs: historical point of view

The frequent appearance of hepatic siderosis/iron overload in nonhemochromatosis CLDs, which increases as liver disease progresses, was first noticed at least 60–70 years ago (7–10). This condition was observed to be most prominent in alcoholic CLD (11). Increased iron absorption (12,13), increased hepatocyte cellular affinity for iron due to liver damage (14), and saturation of total iron-binding capacity (15) were suggested as the possible mechanisms at that time. During succeeding decades the first hypothesis and related issues were worked and discussed actively, but it seems that the issue of saturation of total iron binding capacity has been overlooked.

Studies on iron in liver diseases generally focused on the effect of iron on the progression of liver damage and treatment response in chronic hepatitis C (CHC) during the last decades. Hepcidin studies are another hot topic about hepatic iron overload. After the discovery of this hormone in 2000 (16,17), many studies were published on the status and effect of hepcidin production in CLDs.

* Correspondence: ybuyukas@hacettepe.edu.tr

5. Hepatic siderosis in CLDs: hypotheses on the mechanism and its impact on CLD pathogenesis

5.1. Suggested mechanisms for the hepatic siderosis and objections

Although some theories were suggested, as explained above, hepatic siderosis of CLDs has been generally considered to have uncertain pathogenesis (18), but recent papers generally blamed decreased hepcidin production (19–22) and hepatic parenchymal oxidative stress secondary to inciting factors (21). Although there are also some contrary reports (23–27) it has been generally found that serum (pro)hepcidin level and m-RNA expression in the liver are decreased (or lower than expected considering iron load) in CHC (20,28–39), alcoholic liver disease (40–44), and chronic hepatitis B (CHB) (24,36,45). The decreased hepcidin in CLDs has been considered to be due to the parenchymal injury. However, there are conflicting study results regarding the association of the hepcidin level with liver parenchymal health (i.e. inflammatory activity and fibrosis/cirrhosis) (20,24,26,28,31,33,34,36,44,46). These conflicting results in both CHC and CHB may stem from the method of expressing hepcidin level and/or studying patients in different stages of CLD. It has been shown that hepcidin in relation to iron load (hepcidin:ferritin ratio) was reduced with increasing fibrosis in CLD and this ratio might have diagnostic implications as a marker of cirrhosis (36). Alcohol and the hepatitis C virus also may directly suppress hepcidin production independent from liver parenchymal failure (40–43,47). This may be another reason for the absence of a correlation between liver fibrosis and hepcidin level in some studies.

Decreased hepcidin is thought to lead to increased iron absorption and hepatic deposition. However, although a correlation between hepatic siderosis and hepcidin level has been consistently reported (20,26,31,33,36), the direction of this correlation, i.e. negative (36) or positive (20,26,31,33), was not consistent between studies.

In addition to the above-mentioned conflicting reports on hepcidin production and its correlations with liver parenchymal health and siderosis, the following subjects also raise suspicion about a primarily hepcidin-dependent mechanism in CLD-related hepatic siderosis: normal serum iron level and cellular distribution of hepatic siderosis in CLDs are not compatible with a hepcidin-dependent mechanism. Hereditary hemochromatosis (HHs) types I–III, including HFE-associated HH (type I HH), are associated with inadequately decreased production of hepcidin. In consequence, the decreasing inhibitory effect of hepcidin on duodenal iron absorption leads to clinical iron overload. In this disease, hepcidin is not produced adequately in spite of iron overload due to a defect in the body's iron-sensing mechanism (48). Serum iron level is almost always elevated in HFE-associated

iron overload. As the iron overload is related to increased intestinal absorption, iron comes to the liver through the portal vein and typically there is a decreasing gradient of iron staining from periportal to centrilobular areas until late stages (49,50). The hepatic siderosis of CLD does not fit this example. Serum iron level is frequently not increased and cellular distribution of hepatic iron staining pattern is mixed, indicating a complex mechanism (including release of iron from damaged hepatocytes) instead of a hepcidin-related mechanism (49,51).

The hepatic siderosis observed in nonhemochromatosis CLDs is frequently not associated with systemic or even hepatic iron overload. Systemic iron load is very low even in alcohol-related cirrhosis with prominent hepatic siderosis compared to hemochromatosis (11,52–55). Appearance of hepatic siderosis in spite of low iron load in CLDs suggests that the mechanism of siderosis is not an increased iron entrance into the body, but improper management of iron and/or the tendency of the diseased liver to accumulate iron.

5.2. Impact of siderosis in CLD pathogenesis and objections

Iron-related tissue damage has long been known (56). Animal experiments and studies in hereditary and secondary iron overload states proved that increased hepatocellular iron load may cause lytic necrosis of the hepatocytes and mild chronic inflammation (57–61). These necroinflammatory changes may progress to fibrosis and cirrhosis. Removal of excess iron before the cirrhotic stage may result in regression of the fibrosis (62–65). What about nonhemochromatosis CLDs? Many studies (66–80) concluded that hepatic siderosis is associated with worse necroinflammatory activity, and excessive iron in CHC is probably a cofactor supporting the progression of liver parenchymal damage and increasing fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Many researchers have also found that hepatic iron accumulation has a negative correlation with response to antiviral therapy (74,81–99). Iron elimination by phlebotomy improves elevated serum aminotransferase levels (83,84,100–117), histopathology (100,118–122), and enhanced lipid peroxidation (123); increases the probability of response to antiviral treatment (84,106,114,118,120,124,125); and decreases HCC risk in CHC patients (119,126,127).

Hepatic iron also enhances liver lesions caused by alcohol (128). Alcohol catabolism in the liver by cytochrome p450, subfamily IIE (CYP2E1), results in generation of reactive oxygen species, such as hydrogen peroxide (H_2O_2) (129). H_2O_2 is poorly reactive in the absence of transition metal ions, such as iron. Iron catalyzes the Fenton reaction, which leads to conversion of H_2O_2 to hydroxyl radical. Hydroxyl radical, which is indiscriminately reactive, causes tissue injury and fibrosis (129,130).

Hepatic siderosis is also common in CHB, including noncirrhotic patients (131,132). Liver iron deposits in CHB are associated with higher necroinflammatory activity and fibrosis, too. Therefore, it has been suggested that excess iron might be a factor contributing to the aggressive disease course also for CHB (131,132).

Histological evaluation of the liver in insulin resistance-associated iron overload showed a good correlation between fibrosis and iron accumulation, too (5,133).

In addition to fibrosis and cirrhosis, hepatic iron overload in CLD is also associated with porphyria cutanea tarda (134) and HCC (22,135–137).

Some objections can also be proposed against the above-mentioned considerations related to the role of siderosis in the pathogenesis of CLD: iron overload has a benign course in primary hemochromatosis (138). Practically there is no cirrhosis risk if the serum ferritin level is below 1000 mg/L (139). Thus, the siderosis of CLD, which is generally not associated even with hepatic iron overload, should be just a contributing factor if it is not only a consequence of the disease. There are conflicting reports related to the effect of hepatic siderosis on the course of CHC. Although many studies have suggested that excessive iron is a cofactor promoting progression of liver damage and increasing the risks of fibrosis, cirrhosis, and HCC, as summarized above, some contrary reports have also been published (54,140–155). D'Souza et al. (142) reported that hepatic siderosis, which is quite common in CHC, had no effect on disease progression. Consequently, it should be a result instead of a reason in the disease pathogenesis. Thorburn et al. (143) concluded that neither the concentration of liver iron nor associated hereditary hemochromatosis had significant roles in the progression of HCV-related liver injury. Sajjad et al. (156) could not observe a correlation between hepatic iron and fibrosis.

Although many studies (including 4 randomized controlled studies and one metaanalysis) have indicated an enhanced response to antiviral treatment with phlebotomies in CHC as mentioned before (84,114,118,120,124,125,157), contrary reports (including 3 randomized controlled studies) are also frequent (100,103,106–108,158–163). The effect of iron removal on CHB has been rarely investigated. Bayraktar et al. (164) reported better biochemical, histological, and serological response in CHB cases treated with interferon plus iron chelator deferoxamine compared to a group receiving only interferon.

6. Hypotransferrinemia as a cause of hepatic siderosis in CLDs

Nonhemochromatosis cirrhosis, especially in advanced stages, is known to frequently cause a hemochromatosis-like phenotype both histologically and also in serum iron tests (i.e. increased transferrin saturation and ferritin) (10,165–169).

An autopsy study showed that the iron overload of advanced cirrhosis might even cause cardiac and pancreatic siderosis in some cases (170). The iron overload phenotype of advanced cirrhosis is closely associated with hypotransferrinemia (166). In these cases the main reason for the increased TF saturation is not an elevated serum iron level, but rather the diminished serum TF (i.e. total iron-binding capacity) level. It was shown that as hepatic parenchymal failure progresses, serum total iron binding capacity (i.e. TF activity) decreases (166,171–175) and consequently TS increases. Increased TS was found to be a good predictor of the status of hepatic iron deposits (and fibrosis) in CHC (34,71,176,177). As there is a correlation between iron accumulation and fibrosis (66,67,70,178–184), which is the hallmark of hepatic cirrhosis, it can be concluded that hepatic siderosis might be both a contributing factor for and an indirect consequence of hepatic parenchymal fibrosis (due to decreased synthesis capacity) (166).

7. More on atransferrinemia/hypotransferrinemia, and nontransferrin-bound iron

Congenital atransferrinemia (hypotransferrinemia) (OMIM 209300) is a very rare recessive disorder caused by mutation in the TF gene on chromosome 3q22.1 (185,186). Only 11 cases had been described by 2007 (187). Serum TF level is severely depressed, approximately 1/10 to 1/20 of normal. It is characterized by microcytic anemia and iron overload. The first known case was described by Heilmeyer et al. in 1961 (188). Death occurred from heart failure in this case. Severe hemosiderosis of the heart and liver was found at autopsy.

Besides TF iron, which is the normal form of circulating iron, nontransferrin-bound iron (NTBI) has been identified in the plasma of patients with various diseases in which TF saturation is significantly increased (189). When the carrying capacity of TF is exceeded (due to increased serum iron and/or decreased TF), NTBI appears in the plasma. In hypotransferrinemic mice, the liver and pancreas rapidly cleared absorbed or injected NTBI, suggesting the existence of NTBI uptake system(s) (190). We could not find any published study on NTBI in CLDs or cirrhosis. The lowered serum TF level and the consequent increased TF saturation in cirrhosis may result in the appearance of plasma NTBI, which is avidly taken up by the hepatocytes.

8. Treatments directed toward hepatic siderosis: could TF or hepcidin be treatment agents?

There are experiences indicating the potential benefit of iron removal in CLDs. As stated above, nearly all related studies have concluded that phlebotomy with or without iron restriction was effective in reducing serum transaminase levels in patients with CHC (83,84,100–117). Hepatic iron removal may also improve liver histopathology (100,118–122) and HCC risk (119,126,127).

Could TF and/or hepcidin be used as treatment agents for the hepatic siderosis in CLD/cirrhosis? Human and murine atransferrinemia/hypotransferrinemia cases showed us that TF can be replaced by plasma infusions or by using the purified molecule. TF has a plasma half-life of 8–10 days, which makes the replacement relatively easier (191). Whether TF or hepcidin replacements could be useful in CLD/cirrhosis is an exciting question, but hepcidin has a relatively short half-life, and with present technologies, it is very expensive to produce it at the doses required. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice. They have been shown to prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis (192,193).

9. What further studies related to iron in CLD are needed with priority?

1. NTBI in CLD and its association with hepatic siderosis and serum iron tests would be an interesting study topic. A correlation between NTBI and hepatic siderosis

proves that the excess liver iron comes from the blood. 2. If NTBI is elevated in CLD, how does transferrin replacement by plasma infusions (or probably minihepcidins in future) change serum iron tests and NTBI level? The findings may provide clues regarding potential roles of transferrin and hepcidin analogs in the treatment of hepatic siderosis.

In conclusion, although the topic of CLDs and iron has been extensively studied, the studies have been repetitively focused on a relatively narrow scope of this wide subject. There is a high level of conflicts in some issues. There are enough data to accept that iron metabolism problems and hepatic siderosis get more frequent/severe as CLD progresses. The mechanism of hepatic siderosis in CLD, the role of iron in the disease pathogenesis, and potential benefits of its removal are contradictory issues. There have been ongoing efforts to develop drugs that mimic hepcidin activity. In the future, such agents targeting iron metabolism defects should also be evaluated in hepatic siderosis related to CLDs.

References

1. Beaumont C, Vaulont S. Iron homeostasis. In: Beaumont C, Beris P, Beuzard Y, Brugnara C, editors. Disorders of Iron Homeostasis, Erythrocytes, Erythropoiesis. Paris, France: European School of Haematology; 2006. pp. 392-406.
2. Fleming RE, Sly WS. Hpcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. *P Natl Acad Sci USA* 2001; 98: 8160-8162.
3. Batts KP. Iron overload syndromes and the liver. *Mod Pathol* 2007; 20 (Suppl.): S31-39.
4. Riva A, Trombini P, Mariani R, Salvioni A, Coletti S, Bonfadini S, Paolini V, Pozzi M, Facchetti R, Bovo G et al. Reevaluation of clinical and histological criteria for diagnosis of dysmetabolic iron overload syndrome. *World J Gastroenterol* 2008; 14: 4745-4752.
5. Turlin B, Mendler MH, Moirand R, Guyader D, Guillygomarch A, Deugnier Y. Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. *Am J Clin Pathol* 2001; 116: 263-270.
6. Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, Le Gall JY, Brissot P, David V, Deugnier Y. Insulin resistance-associated hepatic iron overload. *Gastroenterology* 1999; 117: 1155-1163.
7. Herbut PA, Tamaki HT. Cirrhosis of the liver and diabetes as related to hemochromatosis. *Am J Clin Pathol* 1946; 16: 640-650.
8. MacDonald RA. Idiopathic hemochromatosis. A variant of portal cirrhosis and idiopathic hemosiderosis. *Arch Intern Med* 1961; 107: 606-616.
9. Zimmerman HJ, Chomet B, Kulesh MH, McWhorter CA. Hepatic hemosiderin deposits. Incidence in 558 biopsies from patients with and without intrinsic hepatic disease. *Arch Intern Med* 1961; 107: 494-503.
10. Ludwig J, Hashimoto E, Porayko MK, Moyer TP, Baldus WP. Hemosiderosis in cirrhosis: a study of 447 native livers. *Gastroenterology* 1997; 112: 882-888.
11. Barry M, Cartei G, Sherlock S. Measurement of iron stores in cirrhosis using diethylenetriamine penta-acetic acid. *Gut* 1970; 11: 899-904.
12. Callender ST, Malpas JS. Absorption of iron in cirrhosis of liver. *Br Med J* 1963; 2: 1516-1518.
13. Friedman BI, Schaefer JW, Schiff L. Increased iron-59 absorption in patients with hepatic cirrhosis. *J Nucl Med* 1966; 7: 594-602.
14. Golberg L, Smith JP. Iron overloading and hepatic vulnerability. *Am J Pathol* 1960; 36: 125-149.
15. Schwartz SO. Exogenous hemochromatosis; concept and general description. *Am J Clin Pathol* 1956; 26: 744-749.
16. Krause A, Neitz S, Mägert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. *FEBS Lett* 2000; 480: 147-150.
17. Park CH, Valore EV, Waring AJ, Ganz T. Hpcidin, a urinary antimicrobial peptide synthesized in the liver. *J Biol Chem* 2001; 276: 7806-7810.
18. Batts KP. Iron overload syndromes and the liver. *Mod Pathol* 2007; 20 (Suppl. 1): S31-39.

19. D tivaud L, Nemeth E, Boudjema K, Turlin B, Troadec MB, Leroyer P, Ropert M, Jacquelinet S, Courselaud B, Ganz T et al. Hcpidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. *Blood* 2005; 106: 746-748.
20. Girelli D, Pasino M, Goodnough JB, Nemeth E, Guido M, Castagna A, Busti F, Camprostrini N, Martinelli N, Vantini I et al. Reduced serum hepcidin levels in patients with chronic hepatitis C. *J Hepatol* 2009; 51: 845-852.
21. Fargion S, Valenti L, Fracanzani AL. Beyond hereditary hemochromatosis: new insights into the relationship between iron overload and chronic liver diseases. *Dig Liver Dis* 2011; 43: 89-95.
22. Hino K, Nishina S, Hara Y. Iron metabolic disorder in chronic hepatitis C: mechanisms and relevance to hepatocarcinogenesis. *J Gastroenterol Hepatol* 2013; 28 (Suppl. 4): 93-98.
23. Lee SH, Jeong SH, Park YS, Hwang JH, Kim JW, Kim N, Lee DH. Serum prohepcidin levels in chronic hepatitis C, alcoholic liver disease, and nonalcoholic fatty liver disease. *Korean J Hepatol* 2010; 16: 288-294.
24. Olmez OF, Gurel S, Yilmaz Y. Plasma prohepcidin levels in patients with chronic viral hepatitis: relationship with liver fibrosis. *Eur J Gastroenterol Hepatol* 2010; 22: 461-465.
25. Jaroszewicz J, Rogalska M, Flisiak I, Flisiak R. Successful antiviral therapy is associated with a decrease of serum prohepcidin in chronic hepatitis C. *World J Gastroenterol* 2010; 16: 1747-1752.
26. Lin TJ, Liao LY, Chou JM, Liu SO, Wang CK. Serum prohepcidin levels correlate with hepatic iron stores in chronic hepatitis C patients. *Hepatogastroenterology* 2009; 56: 1146-1151.
27. Wang XH, Cheng PP, Jiang F, Jiao XY. The effect of hepatitis B virus infection on hepcidin expression in hepatitis B patients. *Ann Clin Lab Sci* 2013; 43: 126-134.
28. Tsochatzis E, Papatheodoridis GV, Koliarakis V, Hadziyannis E, Kafiri G, Manesis EK, Mamalaki A, Archimandritis AJ. Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C. *J Viral Hepat* 2010; 17: 800-806.
29. Jaroszewicz J, Rogalska M, Flisiak R. Serum prohepcidin reflects the degree of liver function impairment in liver cirrhosis. *Biomarkers* 2008; 13: 478-485.
30. Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. *Hepatology* 2008; 48: 1420-1429.
31. Fujita N, Sugimoto R, Motonishi S, Tomosugi N, Tanaka H, Takeo M, Iwasa M, Kobayashi Y, Hayashi H, Kaito M et al. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. *J Hepatol* 2008; 49: 702-710.
32. Nishina S, Hino K, Korenaga M, Vecchi C, Pietrangelo A, Mizukami Y, Furutani T, Sakai A, Okuda M, Hidaka I et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. *Gastroenterology* 2008; 134: 226-238.
33. Fujita N, Sugimoto R, Takeo M, Urawa N, Mifuji R, Tanaka H, Kobayashi Y, Iwasa M, Watanabe S, Adachi Y et al. Hcpidin expression in the liver: relatively low level in patients with chronic hepatitis C. *Mol Med* 2007; 13: 97-104.
34. Sikorska K, Romanowski T, Stalke P, Izycka Swieszewska E, Bielawski KP. Association of hepcidin mRNA expression with hepatocyte iron accumulation and effects of antiviral therapy in chronic hepatitis C infection. *Hepat Mon* 2014; 14: e21184.
35. Caliskan Y, Yelken B, Ozkok A, Gorgulu N, Yazici H, Telci A, Yildiz A. Lower serum prohepcidin levels associated with lower iron and erythropoietin requirements in hemodialysis patients with chronic hepatitis C. *BMC Nephrol* 2012; 13: 56.
36. Tan TC, Crawford DH, Franklin ME, Jaskowski LA, Macdonald GA, Jonsson JR, Watson MJ, Taylor PJ, Fletcher LM. The serum hepcidin:ferritin ratio is a potential biomarker for cirrhosis. *Liver Int* 2012; 32: 1391-1399.
37. Abd Elmonem E, Tharwa ES, Farag MA, Fawzy A, El Shinnawy SF, Suliman S. Hcpidin mRNA level as a parameter of disease progression in chronic hepatitis C and hepatocellular carcinoma. *J Egypt Natl Canc Inst* 2009; 21: 333-342.
38. Sugimoto R, Fujita N, Tomosugi N, Hara N, Miyachi H, Tanaka H, Takeo M, Nakagawa N, Iwasa M, Kobayashi Y et al. Impaired regulation of serum hepcidin during phlebotomy in patients with chronic hepatitis C. *Hepatol Res* 2009; 39: 619-624.
39. Nagashima M, Kudo M, Chung H, Ishikawa E, Hagiwara S, Nakatani T, Dote K. Regulatory failure of serum prohepcidin levels in patients with hepatitis C. *Hepatol Res* 2006; 36: 288-293.
40. Harrison-Findik DD, Klein E, Crist C, Evans J, Timchenko N, Gollan J. Iron-mediated regulation of liver hepcidin expression in rats and mice is abolished by alcohol. *Hepatology* 2007; 46: 1979-1985.
41. Ohtake T, Saito H, Hosoki Y, Inoue M, Miyoshi S, Suzuki Y, Fujimoto Y, Kohgo Y. Hcpidin is down-regulated in alcohol loading. *Alcohol Clin Exp Res* 2007; 31 (Suppl. 1): S2-8.
42. Harrison-Findik DD, Schafer D, Klein E, Timchenko NA, Kulaksiz H, Clemens D, Fein E, Andriopoulos B, Pantopoulos K, Gollan J. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. *J Biol Chem* 2006; 281: 22974-22982.
43. Bridle K, Cheung TK, Murphy T, Walters M, Anderson G, Crawford DG, Fletcher LM. Hcpidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease. *Alcohol Clin Exp Res* 2006; 30: 106-112.
44. Costa-Matos L, Batista P, Monteiro N, Sim es M, Egas C, Pereira J, Pinho H, Santos N, Ribeiro J, Cipriano MA et al. Liver hepcidin mRNA expression is inappropriately low in alcoholic patients compared with healthy controls. *Eur J Gastroenterol Hepatol* 2012; 24: 1158-1165.
45. Yonal O, Akyuz F, Demir K, Ciftci S, Keskin F, Pinarbasi B, Uyanikoglu A, Issever H, Ozdil S, Boztas G et al. Decreased prohepcidin levels in patients with HBV-related liver disease: relation with ferritin levels. *Dig Dis Sci* 2010; 55: 3548-3551.

46. Aoki CA, Rossaro L, Ramsamooj R, Brandhagen D, Burritt MF, Bowlus CL. Liver hepcidin mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C. *J Clin Gastroenterol* 2005; 39: 71-74.
47. Flanagan JM, Peng H, Beutler E. Effects of alcohol consumption on iron metabolism in mice with hemochromatosis mutations. *Alcohol Clin Exp Res* 2007; 31: 138-143.
48. Gan EK, Powell LW, Olynyk JK. Natural history and management of HFE-hemochromatosis. *Semin Liver Dis* 2011; 31: 293-301.
49. Deugnier Y, Turlin B. Pathology of hepatic iron overload. *World J Gastroenterol* 2007; 13: 4755-4760.
50. Piperno A. Classification and diagnosis of iron overload. *Haematologica* 1998; 83: 447-455.
51. Corengia C, Galimberti S, Bovo G, Vergani A, Arosio C, Mariani R, Redaelli A, Riva A, Cestari C, Pozzi M et al. Iron accumulation in chronic hepatitis C: relation of hepatic iron distribution, HFE genotype, and disease course. *Am J Clin Pathol* 2005; 124: 846-853.
52. Hunt AH, Parr RM, Taylor DM, Trott NG. Relation between cirrhosis and trace metal content of liver with special reference to primary biliary cirrhosis and copper. *Br Med J* 1963; 2: 1498-1501.
53. Hayashi H, Piperno A, Tomosugi N, Hayashi K, Kimura F, Wakusawa S, Yano M, Tatsumi Y, Hattori A, Pelucchi S et al. Patients with chronic hepatitis C may be more sensitive to iron hepatotoxicity than patients with HFE-hemochromatosis. *Intern Med* 2010; 49: 2371-2377.
54. Silva IS, Perez RM, Oliveira PV, Cantagalo MI, Dantas E, Sisti C, Figueiredo-Mendes C, Lanzoni VP, Silva A, Ferraz ML. Iron overload in patients with chronic hepatitis C virus infection: clinical and histological study. *J Gastroenterol Hepatol* 2005; 20: 243-248.
55. Shiono Y, Hayashi H, Wakusawa S, Sanae F, Takikawa T, Yano M, Yoshioka K, Saito H. Body iron stores and iron restoration rate in Japanese patients with chronic hepatitis C as measured during therapeutic iron removal revealed neither increased body iron stores nor effects of C282Y and H63D mutations on iron indices. *Nagoya J Med Sci* 2001; 64: 51-57.
56. Barry M. Iron and the liver. *Gut* 1974; 15: 324-334.
57. Kent G, Volini FI, Minick OT, Orfei E, Delahueriga J. Effect of iron loading upon the formation of collagen in the hepatic injury induced by carbon tetrachloride. *Am J Pathol* 1964; 45: 129-155.
58. Lisboa PE. Experimental hepatic cirrhosis in dogs caused by chronic massive iron overload. *Gut* 1971; 12: 363-368.
59. Deugnier YM, Loréal O, Turlin B, Guyader D, Jouanolle H, Moirand R, Jacquelinet C, Brissot P. Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their biochemical correlations. *Gastroenterology* 1992; 102: 2050-2059.
60. Deugnier Y, Turlin B. Pathology of hepatic iron overload. *Semin Liver Dis* 2011; 31: 260-271.
61. Mackinnon M, Clayton C, Plummer J, Ahern M, Cmielewski P, Ilesley A, Hall P. Iron overload facilitates hepatic fibrosis in the rat alcohol/low-dose carbon tetrachloride model. *Hepatology* 1995; 21: 1083-1088.
62. Barry M, Flynn DM, Letsky EA, Risdon RA. Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress. *Br Med J* 1974; 2: 16-20.
63. Powell LW, Dixon JL, Ramm GA, Purdie DM, Lincoln DJ, Anderson GJ, Subramaniam VN, Hewett DG, Searle JW, Fletcher LM et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. *Arch Intern Med* 2006; 166: 294-301.
64. Falize L, Guillygomarch A, Perrin M, Lainé F, Guyader D, Brissot P, Turlin B, Deugnier Y. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. *Hepatology* 2006; 44: 472-477.
65. Deugnier Y, Turlin B, Ropert M, Cappellini MD, Porter JB, Giannone V, Zhang Y, Griffel L, Brissot P. Improvement in liver pathology of patients with β -thalassaemia treated with deferasirox for at least 3 years. *Gastroenterology* 2011; 141: 1202-1211.
66. Mendes LS, Nita ME, Ono-Nita SK, Mello ES, da Silva LC, Alves VA, Carrilho FJ. Prognostic factors for progression of liver structural lesions in chronic hepatitis C patients. *World J Gastroenterol* 2008; 14: 2522-2528.
67. Beinker NK, Voigt MD, Arendse M, Smit J, Stander IA, Kirsch RE. Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C. *J Hepatol* 1996; 25: 633-638.
68. Chapoutot C, Esslimani M, Joomaye Z, Ramos J, Perney P, Laurent C, Fabbro-Peray P, Larrey D, Domergue J, Blanc F. Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis. *Gut* 2000; 46: 711-714.
69. Pietrangelo A. Metals, oxidative stress, and hepatic fibrogenesis. *Semin Liver Dis* 1996; 16: 13-30.
70. Angelucci E, Muretto P, Nicolucci A, Baronciani D, Erer B, Gaziev J, Ripalti M, Sodani P, Tomassoni S, Visani G et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassaemia following bone marrow transplantation. *Blood* 2002; 100: 17-21.
71. Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, Burra P, Floreani A, Cecchetto A, Naccarato R. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. *J Hepatol* 1995; 22: 449-456.
72. Miyanishi K, Hoki T, Tanaka S, Kato J. Prevention of hepatocellular carcinoma: Focusing on antioxidant therapy. *World J Hepatol* 2015; 7: 593-599.
73. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, Jazwinska EC, Powell LW. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. *Gastroenterology* 1998; 114: 311-318.

74. Fujita N, Sugimoto R, Urawa N, Araki J, Mifuji R, Yamamoto M, Horiike S, Tanaka H, Iwasa M, Kobayashi Y et al. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C. *J Gastroenterol Hepatol* 2007; 22: 1886-1893.
75. Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC; Trent Hepatitis C Study Group. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. *Gut* 2004; 53: 451-455.
76. Bonkovsky HL, Troy N, McNeal K, Banner BF, Sharma A, Obando J, Mehta S, Koff RS, Liu Q, Hsieh CC. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. *J Hepatol* 2002; 37: 848-854.
77. Chino S, Moriyama M, Matsumura H, Ono Y, Arakawa Y. Clinical pathological significance of iron metabolism with chronic hepatitis C patients. *Hepatol Res* 2002; 24: 245.
78. Diwakaran HH, Befeler AS, Britton RS, Brunt EM, Bacon BR. Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. *J Hepatol* 2002; 36: 687-691.
79. Rigamonti C, Andorno S, Maduli E, Morelli S, Pittau S, Nicosia G, Boldorini R, Sartori M. Iron, hepatic stellate cells and fibrosis in chronic hepatitis C. *Eur J Clin Invest* 2002; 32 (Suppl. 1): 28-35.
80. Casaril M, Stanzial AM, Tognella P, Pantalena M, Capra F, Colombari R, Corrocher R. Role of iron load on fibrogenesis in chronic hepatitis C. *Hepatogastroenterology* 2000; 47: 220-225.
81. Olynyk JK, Reddy KR, Di Bisceglie AM, Jeffers LJ, Parker TI, Radick JL, Schiff ER, Bacon BR. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. *Gastroenterology* 1995; 108: 1104-1109.
82. Lebray P, Zylberberg H, Hue S, Poulet B, Carnot F, Martin S, Chretien Y, Pol S, Caillat-Zuckman S, Bréchet C et al. Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C. *J Viral Hepat* 2004; 11: 175-182.
83. Piperno A, Sampietro M, D'Alba R, Roffi L, Fargion S, Parma S, Nicoli C, Corbetta N, Pozzi M, Arosio V et al. Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C. *Liver* 1996; 16: 248-254.
84. Fargion S, Fracanzani AL, Rossini A, Borzio M, Riggio O, Belloni G, Bissoli F, Ceriani R, Ballarè M, Massari M et al. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. *Am J Gastroenterol* 2002; 97: 1204-1210.
85. Clemente MG, Congia M, Lai ME, Lilliu F, Lampis R, Frau F, Frau MR, Faa G, Diana G, Dessi C et al. Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. *J Pediatr* 1994; 125: 123-128.
86. Barton AL, Banner BF, Cable EE, Bonkovsky HL. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. *Am J Clin Pathol* 1995; 103: 419-424.
87. Banner BF, Barton AL, Cable EE, Smith L, Bonkovsky HL. A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C. *Mod Pathol* 1995; 8: 232-238.
88. Olynyk JK, Reddy KR, Di Bisceglie AM, Jeffers LJ, Parker TI, Radick JL, Schiff ER, Bacon BR. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. *Gastroenterology* 1995; 108: 1104-1109.
89. Arber N, Moshkowitz M, Konikoff F, Halpern Z, Hallak A, Santo M, Tiomny E, Baratz M, Gilat T. Elevated serum iron predicts poor response to interferon treatment in patients with chronic HCV infection. *Dig Dis Sci* 1995; 40: 2431-2433.
90. Izumi N, Enomoto N, Uchihara M, Murakami T, Ono K, Noguchi O, Miyake S, Nouchi T, Fujisawa K, Marumo F et al. Hepatic iron contents and response to interferon-alpha in patients with chronic hepatitis C. Relationship to genotypes of hepatitis C virus. *Dig Dis Sci* 1996; 41: 989-994.
91. Ikura Y, Morimoto H, Johmura H, Fukui M, Sakurai M. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. *Am J Gastroenterol* 1996; 91: 1367-1373.
92. Fargion S, Fracanzani AL, Sampietro M, Molteni V, Boldorini R, Mattioli M, Cesana B, Lunghi G, Piperno A, Valsecchi C et al. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. *Eur J Gastroenterol Hepatol* 1997; 9: 497-503.
93. Kaji K, Nakanuma Y, Harada K, Sakai A, Kaneko S, Kobayashi K. Hemosiderin deposition in portal endothelial cells is a histologic marker predicting poor response to interferon-alpha therapy in chronic hepatitis C. *Pathol Int* 1997; 47: 347-352.
94. Kaserer K, Fiedler R, Steindl P, Müller CH, Wrba F, Ferenci P. Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C. *Histopathology* 1998; 32: 454-461.
95. Ferrara F, Ventura P, Vegetti A, Guido M, Abbati G, Corradini E, Fattovich G, Ferrari C, Tagliazucchi M, Carbonieri A et al. Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C. *Am J Gastroenterol* 2009; 104: 605-616.
96. Lin TJ, Liao LY, Lin CL, Chang TA, Liu SO. Hepatic iron influences responses to combination therapy with peginterferon alfa and ribavirin in chronic hepatitis C. *Hepatogastroenterology* 2008; 55: 1412-1415.
97. Bonkovsky HL, Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR, Rogers TE, Banner BF, Sterling RK, Donovan JA, et al. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. *Gastroenterology* 2006; 131: 1440-1451.

98. Distante S, Bjørø K, Hellum KB, Myrvang B, Berg JB, Skaug K, Raknerud N, Bell H. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. *Liver* 2002; 22: 269-275.
99. Kageyama F, Kobayashi Y, Murohisa G, Shimizu E, Suzuki F, Kikuyama M, Souda K, Kawasaki T, Nakamura H. Failure to respond to interferon-alpha 2a therapy is associated with increased hepatic iron levels in patients with chronic hepatitis C. *Biol Trace Elem Res* 1998; 64: 185-196.
100. Di Bisceglie AM, Bonkovsky HL, Chopra S, Flamm S, Reddy RK, Grace N, Killenberg P, Hunt C, Tamburro C, Tavill AS et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. *Hepatology* 2000; 32: 135-138.
101. Kawamura Y, Akuta N, Sezaki H, Hosaka T, Someya T, Kobayashi M, Suzuki F, Suzuki Y, Saitoh S, Arase Y et al. Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection. *J Gastroenterol* 2005; 40: 901-906.
102. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. *Am J Gastroenterol* 1994; 89: 986-988.
103. Guyader D, Boucher E, André P, Even C, Cottareu J, Bianchi A, Gasser P, Mendler MH, Deugnier Y, Brissot P. A pilot study of iron depletion as adjuvant therapy in chronic hepatitis C patients not responding to interferon. *Am J Gastroenterol* 1999; 94: 1696-1698.
104. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. *Am J Gastroenterol* 1994; 89: 986-988.
105. Girelli CM, Mirata C, Casiraghi A. Effect of blood letting on serum aminotransferase levels of patients with chronic hepatitis C and iron overload. *Recenti Prog Med* 1998; 89: 241-244.
106. Fong TL, Han SH, Tsai NC, Morgan TR, Mizokami M, Qian D, Phan C, Goad K, Redeker AG. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C. *J Hepatol* 1998; 28: 369-374.
107. Herrera JL. Iron depletion is not effective in inducing a virologic response in patients with chronic hepatitis C who failed to respond to interferon therapy. *Am J Gastroenterol* 1999; 94: 3571-3575.
108. Jurczyk K, Karpińska E, Wawrzynowicz-Szczyńska M, Morańska I, Nocoń I, Chlubek D, Boroń-Kaczmarek A. State of the iron metabolism in patients with chronic hepatitis C type C does not influence antiviral treatment with interferon and ribavirin. *Hepatogastroenterology* 2008; 55: 557-561.
109. Sumida Y, Kanemasa K, Fukumoto K, Yoshida N, Sakai K. Effects of dietary iron reduction versus phlebotomy in patients with chronic hepatitis C: results from a randomized, controlled trial on 40 Japanese patients. *Intern Med* 2007; 46: 637-642.
110. Tanaka N, Horiuchi A, Yamaura T, Komatsu M, Tanaka E, Kiyosawa K. Efficacy and safety of 6-month iron reduction therapy in patients with hepatitis C virus-related cirrhosis: a pilot study. *J Gastroenterol* 2007; 42: 49-55.
111. Alexander J, Tung BY, Croghan A, Kowdley KV. Effect of iron depletion on serum markers of fibrogenesis, oxidative stress and serum liver enzymes in chronic hepatitis C: results of a pilot study. *Liver Int* 2007; 27: 268-273.
112. Yano M, Hayashi H, Yoshioka K, Kohgo Y, Saito H, Niitsu Y, Kato J, Iino S, Yotsuyanagi H, Kobayashi Y et al. A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan. *J Gastroenterol* 2004; 39: 570-574.
113. Iwasa M, Iwata K, Kaito M, Ikoma J, Yamamoto M, Takeo M, Kuroda M, Fujita N, Kobayashi Y, Adachi Y. Efficacy of long-term dietary restriction of total calories, fat, iron, and protein in patients with chronic hepatitis C virus. *Nutrition* 2004; 20: 368-371.
114. Carlo C, Daniela P, Giancarlo C. Iron depletion and response to interferon in chronic hepatitis C. *Hepatogastroenterology* 2003; 50: 1467-1471.
115. Iwasa M, Kaito M, Ikoma J, Kobayashi Y, Tanaka Y, Higuchi K, Takeuchi K, Iwata K, Watanabe S, Adachi Y. Dietary iron restriction improves aminotransferase levels in chronic hepatitis C patients. *Hepatogastroenterology* 2002; 49: 529-531.
116. Tanaka N, Horiuchi A, Yamaura T, Komatsu M, Yokoyama T, Okaniwa S, Nagaya T, Yoshizawa K, Kiyosawa K, Aoyama T et al. Efficacy and safety of addition of minor bloodletting (petit phlebotomy) in hepatitis C virus-infected patients receiving regular glycyrrhizin injections. *J Gastroenterol* 2009; 44: 577-582.
117. Sartori M, Andorno S, Rigamonti C, Boldorini R. Chronic hepatitis C treated with phlebotomy alone: biochemical and histological outcome. *Dig Liver Dis* 2001; 33: 157-162.
118. Fontana RJ, Israel J, LeClair P, Banner BF, Tortorelli K, Grace N, Levine RA, Fiarman G, Thiim M, Tavill AS et al. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. *Hepatology* 2000; 31: 730-736.
119. Kato J, Kobune M, Nakamura T, Kuroiwa G, Takada K, Takimoto R, Sato Y, Fujikawa K, Takahashi M, Takayama T et al. Normalization of elevated hepatic 8-hydroxy-2'-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. *Cancer Res* 2001; 61: 8697-8702.
120. Van Thiel DH, Friedlander L, Fagioli S, Wright HI, Irish W, Gavalier JS. Response to interferon alpha therapy is influenced by the iron content of the liver. *J Hepatol* 1994; 20: 410-415.
121. Sartori M, Andorno S, Rossini A, Boldorini R, Bozzola C, Carmagnola S, Del Piano M, Albano E. Phlebotomy improves histology in chronic hepatitis C males with mild iron overload. *World J Gastroenterol* 2010; 16: 596-602.

122. Sartori M, Andorno S, Rossini A, Boldorini R, Bozzola C, Carmagnola S, Del Piano M, Albano E. A case-control histological study on the effects of phlebotomy in patients with chronic hepatitis C. *Eur J Gastroenterol Hepatol* 2011; 23: 1178-1184.
123. Kageyama F, Kobayashi Y, Kawasaki T, Toyokuni S, Uchida K, Nakamura H. Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation in chronic hepatitis C. *Am J Gastroenterol* 2000; 95: 1041-1050.
124. Desai TK, Jamil LH, Balasubramaniam M, Koff R, Bonkovsky HL. Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials. *Dig Dis Sci* 2008; 53: 815-822.
125. Van Thiel DH, Friedlander L, Molloy PJ, Kania RJ, Fagioli S, Wright HI, Gasbarrini A, Caraceni P. Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy. *Hepatogastroenterology* 1996; 43: 1557-1561.
126. Nirei K, Matsuoka S, Nakamura H, Matsumura H, Moriyama M. Incidence of hepatocellular carcinoma reduced by phlebotomy treatment in patients with chronic hepatitis C. *Intern Med* 2015; 54: 107-117.
127. Kato J, Miyanishi K, Kobune M, Nakamura T, Takada K, Takimoto R, Kawano Y, Takahashi S, Takahashi M, Sato Y et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. *J Gastroenterol* 2007; 42: 830-836.
128. Ganne-Carrié N, Christidis C, Chastang C, Ziol M, Chapel F, Imbert-Bismut F, Trinchet JC, Guettier C, Beaugrand M. Liver iron is predictive of death in alcoholic cirrhosis: a multivariate study of 229 consecutive patients with alcoholic and/or hepatitis C virus cirrhosis: a prospective follow up study. *Gut* 2000; 46: 277-282.
129. Purohit V, Russo D, Salin M. Role of iron in alcoholic liver disease: introduction and summary of the symposium. *Alcohol* 2003; 30: 93-97.
130. Halliwell B, Clement MV, Long LH. Hydrogen peroxide in the human body. *FEBS Lett* 2000; 486: 10-13.
131. Martinelli AL, Filho AB, Franco RF, Tavella MH, Ramalho LN, Zucoloto S, Rodrigues SS, Zago MA. Liver iron deposits in hepatitis B patients: association with severity of liver disease but not with hemochromatosis gene mutations. *J Gastroenterol Hepatol* 2004; 19: 1036-1041.
132. Sebastiani G, Tempesta D, Alberti A. Hepatic iron overload is common in chronic hepatitis B and is more severe in patients coinfecting with hepatitis D virus. *J Viral Hepat* 2012; 19: e170-176.
133. Nelson JE, Wilson L, Brunt EM, Yeh MM, Kleiner DE, Unalp-Arida A, Kowdley KV; Nonalcoholic Steatohepatitis Clinical Research Network. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. *Hepatology* 2011; 53: 448-457.
134. Kushner JP, Steinmuller DP, Lee GR. The role of iron in the pathogenesis of porphyria cutanea tarda. II. Inhibition of uroporphyrinogen decarboxylase. *J Clin Invest* 1975; 56: 661-667.
135. Nahon P, Ganne-Carrié N, Trinchet JC, Beaugrand M. Hepatic iron overload and risk of hepatocellular carcinoma in cirrhosis. *Gastroenterol Clin Biol* 2010; 34: 1-7.
136. Sorrentino P, D'Angelo S, Ferbo U, Micheli P, Bracigliano A, Vecchione R. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. *J Hepatol* 2009; 50: 351-357.
137. Ko C, Siddaiah N, Berger J, Gish R, Brandhagen D, Sterling RK, Cotler SJ, Fontana RJ, McCashland TM, Han SH et al. Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. *Liver Int* 2007; 27: 1394-1401.
138. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. *Lancet* 2002; 359: 211-218.
139. Waalen J, Felitti VJ, Gelbart T, Beutler E. Screening for hemochromatosis by measuring ferritin levels: a more effective approach. *Blood* 2008; 111: 3373-3376.
140. Guyader D, Thirouard AS, Erdtmann L, Rakba N, Jacquelinet S, Danielou H, Perrin M, Jouanolle AM, Brissot P, Deugnier Y. Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C. *J Hepatol* 2007; 46: 587-595.
141. Nahon P, Sutton A, Rufat P, Ziol M, Thabut G, Schischmanoff PO, Vidaud D, Charneau N, Couvert P, Ganne-Carrie N et al. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. *Gastroenterology* 2008; 134: 102-110.
142. D'Souza RF, Feakins R, Mears L, Sabin CA, Foster GR. Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis C. *Aliment Pharmacol Ther* 2005; 21: 519-524.
143. Thorburn D, Curry G, Spooner R, Spence E, Oien K, Halls D, Fox R, McCrudden EA, MacSween RN, Mills PR. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. *Gut* 2002; 50: 248-252.
144. Pirisi M, Scott CA, Avellini C, Toniutto P, Fabris C, Soardo G, Beltrami CA, Bartoli E. Iron deposition and progression of disease in chronic hepatitis C. Role of interface hepatitis, portal inflammation, and HFE missense mutations. *Am J Clin Pathol* 2000; 113: 546-554.
145. Haque S, Chandra B, Gerber MA, Lok AS. Iron overload in patients with chronic hepatitis C: a clinicopathologic study. *Hum Pathol* 1996; 27: 1277-1281.
146. Jaskiewicz K, Banach L, Lancaster E. Hepatic siderosis, fibrosis and cirrhosis: the association with hepatocellular carcinoma in high-risk population. *Anticancer Res* 1997; 17: 3897-3899.

147. Younossi ZM, Gramlich T, Bacon BR, Matteoni CA, Boparai N, O'Neill R, McCullough AJ. Hepatic iron and nonalcoholic fatty liver disease. *Hepatology* 1999; 30: 847-850.
148. Won JE, Jeong SH, Chung JI, Lee JH, Hwang SH, Kim JW, Lee SH, Kim N, Park YS, Lee DH et al. Hepatic iron, serum ferritin, HFE mutation, and hepatic fibrosis in chronic hepatitis C. *Intervirology* 2009; 52: 239-246.
149. Guyader D, Thirouard AS, Erdtmann L, Rakba N, Jacquelinet S, Danielou H, Perrin M, Jouanolle AM, Brissot P, Deugnier Y. Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C. *J Hepatol* 2007; 46: 587-595.
150. Lin TJ, Liao LY, Lin SY, Lin CL, Chang TA. Influence of iron on the severity of hepatic fibrosis in patients with chronic hepatitis C. *World J Gastroenterol* 2006; 12: 4897-4901.
151. Fernández-Rodríguez CM, Gutiérrez ML, Serrano PL, Lledó JL, Santander C, Fernández TP, Tomás E, Cacho G, Nevado M, Casas ML. Factors influencing the rate of fibrosis progression in chronic hepatitis C. *Dig Dis Sci* 2004; 49: 1971-1976.
152. Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, Massarenti P, Piga A, Marchesini G, Rizzetto M. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. *Hepatology* 2004; 39: 179-187.
153. Ebara M, Fukuda H, Hatano R, Yoshikawa M, Sugiura N, Saisho H, Kondo F, Yukawa M. Metal contents in the liver of patients with chronic liver disease caused by hepatitis C virus. Reference to hepatocellular carcinoma. *Oncology* 2003; 65: 323-330.
154. Larson AM, Taylor SL, Bauermeister D, Rosoff L Jr, Kowdley KV. Pilot study of the relationship between histologic progression and hepatic iron concentration in chronic hepatitis C. *J Clin Gastroenterol* 2003; 37: 406-411.
155. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. *Hepatology* 1999; 29: 1215-1219.
156. Sajjad S, Garcia M, Malik A, Van Thiel DH. Hepatic iron quantitation and its relationship with disease measures and histologically assessed iron content. *Dig Dis Sci* 2008; 53: 1390-1394.
157. Tsai NC, Zuckerman E, Han SH, Goad K, Redeker AG, Fong TL. Effect of iron depletion on long-term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy. *Am J Gastroenterol* 1997; 92: 1831-1834.
158. Pereira PS, Silva IS, Uehara SN, Emori CT, Lanzoni VP, Silva AE, Ferraz ML. Chronic hepatitis C: hepatic iron content does not correlate with response to antiviral therapy. *Rev Inst Med Trop Sao Paulo* 2009; 51: 331-336.
159. Gentile I, Viola C, Paesano L, D'Onofrio M, D'Agostino E, Cerini R, Borrelli F, Piazza M, Borgia G. Iron depletion before HCV antiviral therapy: a pilot, randomized, controlled trial. *J Clin Apher* 2009; 24: 190-196.
160. Souza RM, Freitas LA, Lyra AC, Moraes CF, Braga EL, Lyra LG. Effect of iron overload on the severity of liver histologic alterations and on the response to interferon and ribavirin therapy of patients with hepatitis C infection. *Braz J Med Biol Res* 2006; 39: 79-83.
161. Hofer H, Osterreicher C, Jessner W, Penz M, Steindl-Munda P, Wrba F, Ferenci P. Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. *J Hepatol* 2004; 40: 1018-1022.
162. Sievert W, Pianko S, Warner S, Bowden S, Simpson I, Bowden D, Locarnini S. Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major. *Am J Gastroenterol* 2002; 97: 982-987.
163. Guyader D, Boucher E, André P, Even C, Cottreau J, Bianchi A, Gasser P, Mendler MH, Deugnier Y, Brissot P. A pilot study of iron depletion as adjuvant therapy in chronic hepatitis C patients not responding to interferon. *Am J Gastroenterol* 1999; 94: 1696-1698.
164. Bayraktar Y, Koseoglu T, Somner C, Kayhan B, Temizer A, Uzunalimoglu B, De Maria N, Van Thiel DH. The use of deferoxamine infusions to enhance the response rate to interferon-alpha treatment of chronic viral hepatitis B. *J Viral Hepat* 1996; 3: 129-135.
165. Deugnier Y, Turlin B, le Quilleuc D, Moirand R, Loréal O, Messner M, Meunier B, Brissot P, Launois B. A reappraisal of hepatic siderosis in patients with end-stage cirrhosis: practical implications for the diagnosis of hemochromatosis. *Am J Surg Pathol* 1997; 21: 669-675.
166. Büyükaşık NS, Nadir I, Akin FE, Çakal B, Kav T, Ersoy O, Büyükaşık Y. Serum iron parameters in cirrhosis and chronic hepatitis: detailed description. *Turk J Gastroenterol* 2011; 22: 606-611.
167. Kayali Z, Rangelov R, Mitros F, Shufelt C, Elmi F, Rayhill SC, Schmidt WN, Brown KE. Hemosiderosis is associated with accelerated decompensation and decreased survival in patients with cirrhosis. *Liver Int* 2005; 25: 41-48.
168. Arain SA, Kazi TG, Afridi HI, Talpur FN, Mughal MA, Shah F, Arain SS, Panhwar AH. Estimation of copper and iron burden in biological samples of various stages of hepatitis C and liver cirrhosis patients. *Biol Trace Elem Res* 2014; 160: 197-205.
169. Hattori H. High prevalence of haemosiderin accumulation in the cytoplasm of gastric glands in patients with liver cirrhosis. *J Clin Pathol* 2004; 57: 621-624.
170. Abu Rajab M, Guerin L, Lee P, Brown KE. Iron overload secondary to cirrhosis: a mimic of hereditary haemochromatosis? *Histopathology* 2014; 65: 561-569.
171. Vagu C, Sultana C, Ruta S. Serum iron markers in patients with chronic hepatitis C infection. *Hepat Mon* 2013; 13: e13136.
172. Cho HJ, Kim SS, Ahn SJ, Park JH, Kim DJ, Kim YB, Cho SW, Cheong JY. Serum transferrin as a liver fibrosis biomarker in patients with chronic hepatitis B. *Clin Mol Hepatol* 2014; 20: 347-354.

173. Potter BJ, Chapman RW, Nunes RM, Sorrentino D, Sherlock S. Transferrin metabolism in alcoholic liver disease. *Hepatology* 1985; 5: 714-721.
174. Mao W, Hu Y, Lou Y, Chen Y, Zhang J. Abnormal serum iron markers in chronic hepatitis B virus infection may be because of liver injury. *Eur J Gastroenterol Hepatol* 2015; 27: 130-136.
175. Lambrecht RW, Sterling RK, Naishadham D, Stoddard AM, Rogers T, Morishima C, Morgan TR, Bonkovsky HL; HALT-C Trial Group. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. *Gastroenterology* 2011; 140: 1490-1500.
176. Fabris C, Toniutto P, Scott CA, Falletti E, Avellini C, Del Forno M, Mattiuzzo M, Branca B, Pirisi M. Serum iron indices as a measure of iron deposits in chronic hepatitis C. *Clin Chim Acta* 2001; 304: 49-55.
177. Metwally MA, Zein CO, Zein NN. Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection. *Am J Gastroenterol* 2004; 99: 286-291.
178. Rigamonti C, Andorno S, Maduli E, Capelli F, Boldorini R, Sartori M. Gender and liver fibrosis in chronic hepatitis: the role of iron status. *Aliment Pharmacol Ther* 2005; 21: 1445-1451.
179. Giannini E, Mastracci L, Botta F, Romagnoli P, Fasoli A, Risso D, Faravelli F, Ceppa P, Lantieri PB, Icardi GC et al. Liver iron accumulation in chronic hepatitis C patients without HFE mutations: relationships with histological damage, viral load and genotype and alpha-glutathione S-transferase levels. *Eur J Gastroenterol Hepatol* 2001; 13: 1355-1361.
180. Sartori M, Andorno S, La Terra G, Boldorini R, Leone F, Pittau S, Zecchina G, Aglietta M, Saglio G. Evaluation of iron status in patients with chronic hepatitis C. *Ital J Gastroenterol Hepatol* 1998; 30: 396-401.
181. Vergani A, Bovo G, Trombini P, Caronni N, Arosio C, Malosio I, Fossati L, Roffi L, Piperno A. Semiquantitative and qualitative assessment of hepatic iron in patients with chronic viral hepatitis: relation with grading, staging and haemochromatosis mutations. *Ital J Gastroenterol Hepatol* 1999; 31: 395-400.
182. Piperno A, Vergani A, Malosio I, Parma L, Fossati L, Ricci A, Bovo G, Boari G, Mancina G. Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations. *Hepatology* 1998; 28: 1105-1109.
183. Hézode C, Cazeneuve C, Coué O, Roudot-Thoraval F, Lonjon I, Bastie A, Duvoux C, Pawlotsky JM, Zafrani ES, Amselem S et al. Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. *J Hepatol* 1999; 31: 979-984.
184. Vidali M, Occhino G, Ivaldi A, Rigamonti C, Sartori M, Albano E. Combination of oxidative stress and steatosis is a risk factor for fibrosis in alcohol-drinking patients with chronic hepatitis C. *Am J Gastroenterol* 2008; 103: 147-153.
185. Hayashi A, Wada Y, Suzuki T, Shimizu A. Studies on familial hypotransferrinemia: unique clinical course and molecular pathology. *Am J Hum Genet* 1993; 53: 201-213.
186. Beutler E, Gelbart T, Lee P, Trevino R, Fernandez MA, Fairbanks VF. Molecular characterization of a case of atransferrinemia. *Blood* 2000; 96: 4071-4074.
187. Aslan D, Crain K, Beutler E. A new case of human atransferrinemia with a previously undescribed mutation in the transferrin gene. *Acta Haematol* 2007; 118: 244-247.
188. Heilmeyer I, Keller W, Vivell O, Keiderling W, Betke K, Woehler F, Schultze HE. Congenital atransferrinemia in a 7-year-old girl. *Dtsch Med Wochenschr* 1961; 86: 1745-1751 (in German).
189. Brissot P, Ropert M, Le Lan C, Loréal O. Non-transferrin bound iron: a key role in iron overload and iron toxicity. *Biochim Biophys Acta* 2012; 1820: 403-410.
190. Craven CM, Alexander J, Eldridge M, Kushner JP, Bernstein S, Kaplan J. Tissue distribution and clearance kinetics of non-transferrin-bound iron in the hypotransferrinemic mouse: a rodent model for hemochromatosis. *P Natl Acad Sci USA* 1987; 84: 3457-3461.
191. Harford JB, Rouault TA, Huebers HA, Klausner RD. Molecular mechanisms of iron metabolism. In: Stamatoyannopoulos G, Nienhuis AW, Majerus PW, Varmus H, editors. *The Molecular Basis of Blood Diseases*. Philadelphia, PA, USA: W.B. Saunders; 1994. pp. 351-378.
192. Preza GC, Ruchala P, Pinon R, Ramos E, Qiao B, Peralta MA, Sharma S, Waring A, Ganz T, Nemeth E. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. *J Clin Invest* 2011; 121: 4880-4888.
193. Ramos E, Ruchala P, Goodnough JB, Kautz L, Preza GC, Nemeth E, Ganz T. Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. *Blood* 2012; 120: 3829-3836.